References
- Colucci WS, Braunwald E. Heart failure: Cardiac function and dysfunction. In: Colucci WS, Editor. Atlas of Heart Diseases, 4th ed. Philadelphia, PA, USA: Blackwell Science. 1995: 128-142.
- Maron BJ, Towbi, JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006; 113(14): 1807-1816.
- Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 117(4): e25-e146.
- Hershberger RE, Lindenfeld J, Mestroni, L, Seidman, CE, Taylor MR, Towbin JA; Heart Failure Society of America. Genetic evaluation of cardiomyopathy--A Heart Failure Society of America practice guideline. J Card Fail 2009; 15(2): 83-97.
- Weigner M, Morgan JP. The causes of dilated cardiomyopathy. UpToDate. 2007; 15(3): 1-10.
- Grenier MA, Osganian SK, Cox GF, Towbin JA, Colan SD, Lurie PR, et al. Design and implementation of the North American pediatric cardiomyopathy registry. Am Heart J. 2000; 139(2 Pt 3): s86-s95.
- Watanabe T, Konii H, Sato K. Emerging roles of cardiotrophin-1 in the pathogenesis and biomarker of atherosclerosis. J. 2018; 1(1): 94-105.
- Abdul-Ghani M, Suen C, Jiang B, Deng Y, Wedrick JJ, Putinski C, et al. Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart. Cell Res. 2017; 27(10): 1195-1215.
- Konii H, Sato K, Kikuchi S, Okiyama H, Watanabe R, Hasegawa A, et al. Stimulatory effects of cardiotrophin 1 on atheroscheloris. Hypertension. 2013; 62(5): 942-950.
- Chomczynski P, Mackey K. Short technical reports. Modificatin of the TRI reagent procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources. Biotechniques. 1995; 19(6): 942-945.
- Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, et al. A molecular basis for familial hypertrophic cardiomyopathy: A cardiac myosin heavy chain gene missense mutation. Cell. 1999; 62(5): 999-1006.
- Thomas DE, Wheeler R, Yousef ZR, Masami ND. The role of echocardiography in guiding management in dilated cardiomyopathy. Eur J Echocardiogr. 2009; 10(8): 15-21.
- Miura K, Nakagawa H, Morikawa Y, Sasayama S, Matsumori A, Hasegawa K, et al. Epidemiology of idiopathic cardiomyopathy in Japan: Results from a nationwide survey. Heart. 2002; 87(2): 126-130.
- Jougasaki M, Tachibana I, Luchner A, Leskinen H, Redfield MM, Burnett JC Jr. Augmented cardiac cardio-trophin-1 in experimental congestive heart failure. Circulation. 2000; 101(1): 14-17.
- Freed DH, Cunnington RH, Dangerfield AL, Sutton JS, Dixon IMC. Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. Cardiovasc Res. 2005; 65(4): 782-792.
- Natal C, Antonia Fortuño M, Restituto P, Bazán A, Colina I, Díez J, et al. Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2008; 294(1): 52-60.
- Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001; 38(5): 1485-90.